Inactivation of smooth muscle tissue

ABSTRACT

Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a non-provisional of U.S. Provisional Application Ser. No.60/610,925 filed Aug. 18, 2004, the entirety of which is incorporated byreference.

BACKGROUND OF THE INVENTION

Asthma is a serious chronic condition. In the United States alone, it isbelieved that asthma affects upward of 15 million Americans. Asthma ischaracterized by (i) bronchoconstriction, (ii) excessive mucusproduction, and (iii) inflammation and swelling of airways. Theseconditions cause widespread and variable airflow obstruction therebymaking it difficult for the asthma sufferer to breathe. Asthma furtherincludes acute episodes or attacks of additional airway narrowing viacontraction of hyper-responsive airway smooth muscle. Other obstructivediseases such as COPD may also have a reversible component caused by oneor more of the above mentioned three elements.

Asthma generally includes excessive mucus production in the bronchialtree. Usually, there is a general increase in bulk (hypertrophy) of thelarge bronchi and chronic inflammatory changes in the small airways. Seefor example, Hogg, J C. The Pathology of Asthma. APMIS 1997;105:735-745. Excessive amounts of mucus are found in the airways andsemisolid plugs of mucus may occlude some small bronchi. Also, the smallairways are narrowed and may show inflammatory changes. See, e.g., KraftM, The Distal Airways: Are they Important in Asthma? Eur Respir J 1999;14:1403-1417. The reversible aspects of COPD include partial airwayocclusion by excess secretions, bronchial wall edema, inflammation ofthe airways and airway narrowing as a result of smooth musclecontraction.

The role of airway smooth muscle and its effect in patients with asthmais gaining increased attention in the medical community. See, forexample, Shore S, Airway Smooth Muscle in Asthma—Not Just More of theSame, 2004 N Engl J Med 351; 6; Jeffery P K. Remodeling in Asthma andChronic Obstructive Lung Diseas., Am J. Respir Crit Care Med 2001; 1645:S28-S38; Global Initiative for Asthma (GINA) Global Strategy for AsthmaManagement and Prevention, NIH/NHLBI, 2002 NIH Publication No 02-3659Furthermore, the literature tends to support the belief that smoothmuscle tissue within the airways is not essential to normal lungphysiology and that the smooth muscle tissue may in fact be a vestigialorgan. In the case of individuals with asthma, the airway smooth musclemay actually cause medical complications. See, for example, Seow C Y,Fredberg J J, Historical Perspective on Airway Smooth Muscle: the Sagaof a Frustrated Cell, 2001 Appl Physiol 91(2):938-952, Mitzner W, AirwaySmooth Muscle: the Appendix of the Lung, 2004 AJRCCM, 169:787-790.

Currently, asthma management includes a combination of stimulusavoidance and pharmacological mediation. Stimulus avoidance includessystematic identification of each type of stimuli and minimization ofcontact with each type of stimuli. It may, however, be impractical andnot always helpful to avoid all potential stimuli.

Pharmacological mediation of asthma includes: (1) long term controlthrough use of anti-inflammatories and long-acting bronchodilators and(2) short term management of acute exacerbations through use ofshort-acting bronchodilators. Both approaches require repeated andregular use of the prescribed drugs. High doses of corticosteroidanti-inflammatory drugs may include serious side effects requiringcareful management. In addition, some patients are resistant to steroidtreatment.

The difficulties involved in patient compliance with pharmacologicmanagement and the difficulties of avoiding asthma triggering stimulusare common barriers to successful asthma management. It follows thatcurrent management techniques are neither completely successful nor freefrom side effects. Aside from the difficulties in these managementtechniques, some individuals may seek a more permanent solution tomanage asthma.

Removal and/or deactivation of a body organ, vestigial or not, ismedically acceptable as long as there is an overall benefit. A fewexamples of such procedures include removal of: body hair, the appendix,wisdom teeth, and portions of the cornea. Moreover, deactivation ofcertain muscles is accepted for cosmetic results. In this latterprocedure, a physician injects botulism toxin type A (i.e., BOTOX®)directly into the corrugator and procerus muscles, preventing them fromcontracting and eventually causing the skin to become smoother,

Additionally, use of RF energy when applied to the airways has beenshown to decrease the ability of smooth muscle tissue to narrow theairways. Danek C J, et al, Reduction in Airway Hyperresponsiveness toMethacholine by the Application of RF Energy in Dogs. 2004 J ApplPhysiol. Jul. 16 doi:10.1152/japplphysiol.01282.2003 (electronicpublication—ahead of print)

In view of the foregoing, there remains an additional need for removaland/or deactivation of certain types of muscle which may contribute toor cause an impaired quality of life. In just one specific example,there remains a need to remove and/or deactivate certain airway smoothmuscle to address the effects of certain pulmonary conditions, includingbut not limited to asthma.

BRIEF SUMMARY OF THE INVENTION

The present invention includes methods of treating smooth muscle tissueto prevent adverse effects resulting from constriction of body passages.Though the approaches discussed below discuss treatment of airway smoothmuscle to prevent bronchoconstriction in cases of pulmonary disorders,it is contemplated that variations of the treatment are not limited toairway smooth muscle. Variations of the treatments and proceduresdescribed herein may be applied to non-airway smooth muscle whereappropriate.

The treatments and procedures described below include methods oftreating individual for hyper-responsiveness of a body passage, wherethe method comprises placing an agent into a blood vessel that suppliesblood to tissue of the body passage, where the agent affects'the abilityof the body passage to constrict.

Also disclosed are methods of reducing the ability of a body passage toconstrict in response to stimulus, where the method comprises altering ablood supply of smooth muscle tissue in the body passage to lessen oreliminate the ability of a portion of the smooth muscle tissue toconstrict the body passage. In this case altering blood flow may includeadding an agent to the blood that affects smooth muscle as discussedherein. Alternatively, or in combination, altering of the blood flow maycomprise slowing or stopping the flow of blood to the target smoothmuscle to affect the smooth muscle tissue.

The agents described herein may include toxins, radioactive agents,viral agents, and/or drugs. Example of such agents includes toxins suchas natural, animal or insect toxins, or engineered toxins; I-131 (Iodine131), laser absorptive dye, agents that bind to constituents of airwaysmooth muscle (e.g., myosin, actin), neutrophils, paralytic agents,embolizing agents, etc. Examples of agents that selectively affectsmooth muscle tissue include: snake myotoxins; anti-bodies that bind toactin or myosin, with the impairment agent bound to the antibody. Theagent may also include microspheres the size of the capillaries at thesmooth muscle. These micropspheres could also contain an additionalagent.

Variations of the invention described herein include procedures andtreatments that deliver a persistent treatment to prevent the ability ofbody passages to constrict.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

FIG. 1 is a cross sectional view of an airway in a healthy lung.

FIG. 2 shows a section through a bronchiole having an airway diametersmaller than that shown in FIG. 1.

FIG. 3 illustrates an airway similar to that of FIG. 1 but in which thesmooth muscle hypertrophied and increased in thickness causing reductionof the airway diameter.

FIG. 4 is a representation of the lungs, airway, pulmonary vessels andbronchial vessels.

FIG. 5 is a representation of the bronchial artery and vein as it runsalong an airway.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to reducing or preventing a body passage fromconstricting by inactivating or therapeutically damaging the smoothmuscle which causes contraction of the body passage. Although theinvention described herein may have applications throughout the body,the variation of the invention described below relates to treatingairway smooth muscle tissue to prevent or reduce constriction of theairways within a lung. As noted above, preventing or reducingconstriction of the airways allows for improved breathing for individualsuffering from a pulmonary condition, such as asthma.

The inventive treatment reduces the ability of the airways to constrict,narrow or to reduce in diameter due to airway smooth muscle contraction.The reduction in the ability of the smooth muscle to contract may lieachieved by treating the smooth muscle itself or by treating othertissues to affect smooth muscle contraction or the response of theairway to the smooth muscle contraction. Treatment may also reduceairway responsiveness or the tendency of the airway, to narrow or toconstrict in response to a stimulus.

The reduction in smooth muscle and surrounding tissue may also have theadded potential benefit of increasing the caliber or diameter of theairways, this benefit reduces the resistance to airflow through theairways. In addition to the use of debulking smooth muscle tissue toopen up the airways, the devices and/or approach of the presentinvention may eliminate smooth muscle altogether by damaging ordestroying the muscle.

In the airways, the smooth muscle is arranged externally to an airway ina generally helical pattern with pitch angles ranging from about −30 toabout +30 degrees. Thus, the treatment of the smooth muscle, which maybe selectively given in an appropriate pattern, interrupts or cutsthrough the helical pattern at a proper pitch and prevents the airwayfrom constricting. Therefore, a variation of the invention may includetreating the airway smooth muscle in one or more sites or in a patternto eliminates contraction of the airways without completely eradicatingsmooth muscle and other airway tissue. Alternatively, a variation of theinvention includes treating at one or a few sites to inactivate all or asignificant portion of the airway smooth muscle.

FIGS. 1 and 2 illustrate cross sections of an airway and a bronchiole,respectively, in a healthy patient. The airway of FIG. 1 is a mediumsized bronchus having an airway diameter D1 of about 3 mm. FIG. 2 showsa section through a bronchiole having an airway diameter D2 of about 1.5mm. Each airway includes a folded inner surface or epithelium 10surrounded by stroma 12 and smooth muscle tissue 14. The larger airwaysincluding the bronchus shown in FIG. 1 also have mucous glands 16 andcartilage 18 surrounding the smooth muscle tissue 14. Nerve fibers 20and blood vessels 22 also surround the airway.

FIG. 3 illustrates, the bronchus of FIG. 1 in which the smooth muscle 14hypertrophied and increased in thickness causing the airway diameter tobe reduced from the diameter D1 to a diameter D3.

In any case, the smooth muscle tissue 14 is responsible for constrictionof the airways. As noted herein, the adverse affects of excessive airwayconstriction may be alleviated by directly inactivating or deactivatingthe function of the airway smooth muscle.

The airway smooth muscle relies upon the bronchial vasculature for itsblood supply. Therefore, any altering of the blood supply in thebronchial system significantly affects the airway smooth muscle ascompared to the remaining airway wall or bronchial tissue. Because ofthis, the airway smooth muscle's blood supply may be treated so that theeffects of the treatment are acceptably limited to the airway smoothmuscle. Furthermore, the blood-air exchange function of the alveoli (themost distal portion of the airway that provides a gas exchangefunction), relies upon a separate vasculature network. So any actionstaken on the bronchial vasculature may be controlled so that they willhave little or no effect upon the remaining circulatory system,including the pulmonary vasculature.

FIG. 4 is a representative illustration of the lungs 2, airways 4,pulmonary arteries 6, pulmonary veins 8, and bronchial veins andarteries 22. To deliver the treatment in accordance with the teachingsdescribed herein, a treatment location is selected. Generally, thebronchial arteries 24 run within the airway wall. It is noted that thelocation or treatment site may be selected either from sensing withinthe airway 4 (e.g., via Doppler sensing), external means by any mode ofnon-invasive detection, and/or by any other means of locating anacceptable site to provide the treatment.

FIG. 4 also illustrates a variation of the treatment where a catheter 40advances into the airways. The catheter 40 may be equipped to performthe procedure as discussed herein. By advancing the catheter 40 throughthe airways, the treatment may be delivered to the bronchial arterywithout having to puncture the pleura.

FIG. 5 shows a representation of an airway 4 terminating into thealveolus 3. As shown, the airway 4, includes a bronchial artery 6 and abronchial vein 8 running exterior to the lumen of the airway. Asillustrated, the bronchial arteries and veins 24 and 26 run externallyalong either side of the main bronchus and follow the branching of theairways 4. The location of the bronchial artery 24 allows for any numberof modes of detection (e.g., Doppler, thermal, etc.) to locate apossible treatment site.

The treatment described herein may be provided via a minimally invasiveapproach. For example, a medical practitioner advances a treatmentdevice 40 (e.g., a bronchoscope carrying a catheter, a catheter, etc.)into the airways 4. Alternatively, or in combination, the medicalpractitioner may apply the treatment from outside the body throughinjection, or even oral administration. Some variations of the treatmentdescribed herein allow for treatment of the airway smooth muscle tissue,which is located in a considerable number of airways, could be appliedin a single or relatively few locations (e.g., one or more sites in thebronchial arteries.) This advantage allows for treatment at relativelyfew sites as opposed to having to treat the entire (or considerableportion) of the bronchial network.

In one variation of the treatment, the medical practitioner injects anagent into the bronchial artery or arteries 24 supplying the airways 4.As noted above, the agent affects the blood supplied to the smoothmuscle tissue within the airway. In turn, the agent reaches the smoothmuscle tissue to deactivate, or impair the function of the smooth muscletissue. As a result, the inability of the smooth muscle tissue toconstrict the airways improves the breathing condition of the patent(e.g., in cases of an asthma attack.)

The agents described herein may include toxins, radioactive agents,viral agents, and/or drugs. Example of such agents includes toxins suchas natural, animal or insect toxins, or engineered toxins, I-131 (Iodine131), laser absorptive dye, agents that bind to constituents of airwaysmooth muscle (e.g., myosin, actin), neutrophils, paralytic agents,embolizing agents, etc. Examples of agents that selectively affectsmooth muscle tissue include: snake myotoxins; anti-bodies that bind toactin or myosin, with the impairment agent bound to the antibody. Theagent may also include microspheres the size of the capillaries at thesmooth muscle. These micropspheres could also contain an additionalagent.

A variation of the treatment may include delivering a second agent whichcounteracts the effect of the first agent. In such a case, the secondagent is provided so that the treatment is limited to the. desired partof the body (e.g., the airways.) For example, if a toxin is applied tothe bronchial artery, a counteracting agent may be introducedsystemically or locally but in a way so that the initial treatment isnot rendered ineffective. For example, if the agent is cyanide thecounteragent or protectant agent could be amyl nitrate Accordingly, asthe agent affect the smooth muscle in the airways, the counteractingagent minimizes adverse effect on other smooth muscle that is not asubject of the treatment. Examples of such counteragents include, but isnot limited to, antivenom. It is also contemplated that instead of acounter-agent, a mechanical filter or binding substance may be used to‘collect’ or deactivate the agent before the agent is able to affectnon-target tissues. Furthermore, a counteractive measure may be appliedto the same effect as a counter agent. For example, an agent may beapplied where the agent may be rendered ineffective under certainenvironments (e.g., upon the application of current, an electric field,or other chemical reaction.)

The counteragent may be provided in such a way that it allows for“dosing” of the agent. For example, the agent may be applied in aconcentration strong enough to have the desired effect, but throughdilution, degradation, or through systemic counteragent (at a dose thatcannot protect the targeted tissues which see a “too strong” dose ofagent) cannot affect other organ systems.

A variation of the treatment described herein includes ligating orreducing flow within the bronchial vessel or vessels so that the agentis trapped or delayed in the desired treatment location until asignificant amount of the agent is absorbed or until the agent decays oris rendered inactive. For example, a radioactive agent with a properlyselected half-life may be used. In this case, reducing the flow of theagent trapping the agent within the bronchial vessels may allow asufficient amount of time to pass so that the radioactive agent decayssufficiently so that any of the agent that passes to other portions ofthe body is rendered sufficiently ineffective to cause any concern ofside effects. This approach of reducing the blood flow may beaccomplished at the arterial side of the flow (i.e,, the inflow side),and/or may be accomplished at the venous side of the flow (i.e., theoutflow side).

In another example of the inventive treatment, the blood supply to thetarget smooth muscle may be interrupted or reduced to starve the smoothmuscle by reducing oxygen supply to the muscle to induce temporary orpermanent deactivation of the muscle. In this variation of thetreatment, the blood supply may be altered by introducing an agent thatoccludes blood flow in the vessel. In some cases, the blood vessels maybe starved of necessary nutrients or otherwise induced to createdamaging toxins on their own. The occluding agent could be any agent,combination of agents and/or devices that restricts blood flow.

Alternatively, or in addition, the blood supply may be altered by simplydamaging the blood vessel or shunting blood flow to a different regionso that blood does not reach the targeted smooth muscle tissue. Forexample, the bronchial artery may be coagulated to stop flow. In anothervariation, the blood flow in the bronchial artery may be shunted to thepulmonary vessels or the bronchial vein. The bronchial vein may also beclosed to accomplish the appropriate result of affecting the smoothmuscle tissue.

The treatment described herein may be combined with other conventionaltreatments. For example, for asthma management, the treatments hereinmay be combined with stimulus avoidance or pharmacological management ofasthma. In addition, the treatments may be combined with the treatmentsdescribed in the following commonly assigned patents and applications.U.S. patent application Ser. No. 09/095,323 filed Jun. 10, 1998; Ser.No. 09/436,455 filed Nov. 8, 1999. U.S. Published application:20030233099A1; 20040010289A1; 20020091379A1. U.S. Pat. Nos. 6,411,852;6,634,363 the entirety of all of which are incorporated by referenceherein so that they may be combined with the inventive procedures andtreatments described herein.

The effectiveness of the treatments and procedures described above maybe further improved through exercise or activation of the target smoothmuscle while the treatment or procedure is in process. For example, thesmooth muscle may be stimulated during treatment to increase its demandfor oxygen from the blood system. In turn, the increased demand foroxygen may cause, either more of the agent to pass to the target smoothmuscle, or in cases where the blood flow is interrupted, the lack ofoxygen causes ischemia of the “activated” smooth muscle at an increasedrate.

In addition, the effectiveness of the treatments and proceduresdescribed herein may be titrated. In this case, the treatment may beperformed under stimulated constriction of the airways. A medicalpractitioner would then observe the effects of the treatment (eitherreal time and/or under direct observation, or through other measurementmodes). Upon reaching the desired effect, the medical practitioner wouldstop the treatment. For example, methocholine, which stimulates smoothmuscle activity, may be placed in the airway to stimulate the smoothmuscle. Alternatively, or in combination, the smooth muscle may bestimulated electrically, or by other stimulus.

The treatments and/or agents described herein may also be combined withtemperature, dyes, or other detectible additives. For example, blood onthe arterial side of the airway smooth muscle may be heated or cooled(alternatively, it may be the agent that is heated or cooled.) Then, bymeasuring the blood flow on the venous side of the airway smooth muscle,one is able to confirm when the agent or effect has passed through thesmooth muscle. For example, one variation of the invention includescooling the agent, injecting the agent into the blood flow, thenmeasuring the temperature of the vein or venous flow. A drop intemperature (or observation of the additive) at this location informsthe medical practitioner that the agent or altered blood passed throughthe smooth muscle.

While the invention has been described in detail with reference to thepreferred embodiments thereof, it will be apparent to one skilled in theart that various changes and modifications can be made and equivalentsemployed, without departing from the present invention. Furthermore, theabove illustrations and descriptions are examples of a number ofnon-exhaustive variations the invention described herein. It iscontemplated that combinations of aspects of specific embodiments orcombinations of the specific embodiments themselves are within the scopeof this disclosure.

1. A method of reducing the ability of a lung airway to narrow, themethod comprising: placing an effective amount of a muscle impairingagent into a blood vessel that supplies blood to tissue of the lungairway, where the muscle impairing agent affects the ability of the lungairway to constrict in response to a stimulus. 2-47. (canceled)
 48. Themethod of claim 1, wherein the blood vessel comprises a bronchialartery.
 49. The method of claim 1, wherein the agent includes one ormore of an artificial toxin, a naturally occurring toxin, a radioactiveagent, a viral agent, a drug, Iodine 131, laser absorptive dyes, anagent that binds to constituents of airway smooth muscle, neutrophils,paralytic agents, and embolizing agents.
 50. The method of claim 1,further comprising delivering a second agent to the body, wherein thesecond agent protects a portion of the body against the effects of theagent.
 51. The method of claim 50, wherein the second agent is deliveredby a mode selected from the group consisting of inhalation, injection,and oral administration.
 52. The method of claim 1, further comprisingstimulating the lung airway.
 53. The method of claim 52, whereinstimulating the lung airway increases absorption of the agent.
 54. Themethod of claim 52, wherein placing the agent comprises injecting theagent in response to an amount of contraction of the airway caused bythe stimulation.
 55. The method of claim 1, further comprising selectinga second vascular site, and reducing blood flow in the second vascularsite to decrease the flow rate of the agent in the blood vessel.
 56. Themethod of claim 1, further comprising monitoring the blood to determinean amount of the agent in the blood.
 57. A method of reducing theability of a lung airway to narrow, the method comprising: placing aneffective amount of an agent into a blood vessel that supplies blood tosmooth muscle tissue of a lung such that the agent reaches the smoothmuscle tissue, wherein the agent affects the smooth muscle tissue,reducing the ability of the lung airway to constrict in response to astimulus.
 58. The method of claim 57, wherein the agent impairs,deactivates, or kills the smooth muscle tissue.
 59. The method of claim57, wherein the blood vessel comprises a bronchial artery.
 60. Themethod of claim 57, wherein the agent includes one or more of anartificial toxin, a naturally occurring toxin, a radioactive agent, aviral agent, a drug, Iodine 131, laser absorptive dyes, an agent thatbinds to constituents of airway smooth muscle, neutrophils, paralyticagents, and embolizing agents.
 61. The method of claim 60, furthercomprising delivering a second agent to the body, wherein the secondagent protects a portion of the body against the effects of the agent.62. The method of claim 61, wherein the second agent is delivered by amode selected from the group consisting of inhalation, injection, andoral administration.
 63. The method of claim 57, further comprisingstimulating the lung airway.
 64. The method of claim 63, whereinstimulating the lung airway increases absorption of the agent.
 65. Themethod of claim 63, wherein placing the agent comprises injecting theagent in response to an amount of contraction of the airway caused bythe stimulation.
 66. The method of claim 57, further comprisingselecting a second vascular site, and reducing blood flow in the secondvascular site to decrease the flow rate of the agent in the bloodvessel.